The partnership will combine MELCO's satellite system expertise and integration capabilities with SWISSto12's proprietary 3D-printing designs and processes.
The partnership follows the opening of Bioactivx's medical-grade filament production and cleanroom print farm facility and its obtainment of HSA approval for its flagship Bioactiv Matrix product.
KLS Martin is leveraging its LCM printers, which are operating under an ISO 13485-certified quality management system, and enabling patient- and case-specific geometries.
Stentra has been cleared by the U.S. Food and Drug Administration (FDA 510(k) K232293) and is in clinical use at leading U.S. cancer centres, including a recently announced collaboration with Stanford Health Care.
Orion has been designed specifically for application within labs and clinics and is said to be capable of manufacturing soft and rigid patient-specific devices.
